A carregar...
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
BACKGROUND: Sorafenib, a multi-kinase inhibitor, is used as a standard therapy for advanced hepatocellular carcinoma (HCC). However, complete remission has not been achieved and the molecular basis of HCC resistance to sorafenib remains largely unknown. Previous studies have shown that fibroblast gr...
Na minha lista:
| Publicado no: | J Exp Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5223586/ https://ncbi.nlm.nih.gov/pubmed/28069043 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0478-9 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|